RBD4059 / Suzhou Ribo - LARVOL DELTA

A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of RBD4059 in Participants with Stable Coronary Artery Disease (clinicaltrials.gov) - P2 | N=30 | Recruiting | Sponsor: Ribocure Pharmaceuticals AB

New P2 trial • Cardiovascular • Coronary Artery Disease

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects (clinicaltrials.gov) - P1 | N=32 | Active, not recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Dec 2025

Enrollment closed • Trial completion date • Trial primary completion date

First-in-human study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of RBD4059, a GalNAc-siRNA drug targeting coagulation factor XI (FXI), in healthy subjects (ESC 2024) - P1 | "As of January 25, 2024, 24 subjects (with follow-up to week 24) with demographics and baseline clinical characteristics shown in Table 1 were enrolled. RBD4059 was well tolerated (Table 2), all related AEs were grade 1. There was no evidence of any clinically relevant bleeding events."

Clinical • P1 data • PK/PD data • Cardiovascular

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | N=64 ➔ 40 | Trial completion date: Mar 2025 ➔ Dec 2024

Enrollment change • Trial completion date

A Single and Multiple Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2024 ➔ Mar 2025

Enrollment open • Trial completion date

Inhibition of Factor XI using a GalNAc-siRNA RBD5049: a novel antithrombotic drug with high potency and long duration (ESC 2023) - "Enoxaparin sodium (Lovenox) with clinical equivalent dose (4 mg/kg) was used as a control. RBD4059 has demonstrated high potency/efficacy and long duration regarding FXI inhibition and with large safety margin. As the first siRNA based molecule targeting FXI, RBD4059 has now entered Phase 1 trial in human healthy volunteers."

Cardiovascular • Thrombosis • Venous Thromboembolism

A Single and Multiple Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Suzhou Ribo Life Science Co. Ltd.

New P1 trial